Combination cohort 1 for Oral Squamous Cell Carcinoma

"This clinical trial is being conducted in UPMC Hillman Cancer Center, Pittsburgh; Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston; UCLA Hematology & Oncology Clinic, Los Angeles; as well as 15 other medical centres."

"Currently this medical trial is not enrolling new participants. It was first published on August 18th 2017 and last updated June 15th 2022. If in search of other studies, there are 7897 trials actively recruiting for oral squamous cell carcinoma patients and 3 clinical trials admitting enrollees for tebotelimab treatment."

"This 24 month clinical trial has the primary objective of determining Maximum Tolerated Dose. Secondary objectives include evaluating Terminal half-life (t1/2), Area Under the Plasma Concentration versus Time Curve (AUC) and Preliminary anti-tumor activity of MGD013 in combination with margetuximab."

"Currently, 3 clinical trials involving tebotelimab are in the midst of being conducted with one trial having reached Phase 3. These research sites span 132 locations across America, mainly situated within Washington D.C.."

"At present, there are 3 active clinical trials of tebotelimab taking place across 57 cities and 15 countries. MacroGenics initiated the first study in 2017 with 353 participants that successfully managed to pass through Phase 1 drug approval stage. Since then, a further 5 studies have been completed."

"Since tebotelimab is currently in its first clinical trial, Power rated it as a 1 on the safety scale - meaning there exists only limited data supporting efficacy and security."

"The information on clinicaltrials.gov displays that this trial, initially posted on August 18th 2017 and last updated June 15th 2022, is not presently seeking participants for enrollment. However, there are 7900 other trials in progress which might be a suitable alternative for prospective patients."